Abstract: The present invention relates to the discovery, identification, and characterization of novel genes encoding proteins that play a role in immune system development and function, collectively termed Nessie. The invention encompasses the described polynucleotides, the encoded proteins, fusion proteins, polypeptides and peptides, genetically engineered animals that either under- or over-express the disclosed sequences, antibodies to the encoded proteins and peptides, host cell expression systems, antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed sequences that can be used for diagnosis, drug screening, clinical trial monitoring and the treatment of diseases and disorders.

Abstract: The invention provides for the identification of all genes, whether known or novel, which are differentially expressed within and among B cells, making possible the characterization of their temporal regulation and function in the B cell response and/or in B cell mediated disorders. Expression profiles, nucleic acids and proteins are provided for differing states of B cells, including resting, naïve, activated, tolerant and immunosuppressed B cells. The present invention makes possible the identification and characterization of targets useful in prognosis, diagnosis, monitoring, rational drug design, and/or therapeutic intervention of immune system disorders.

Abstract: The invention provides for the identification of all genes, whether known or novel, which are differentially expressed within and among B cells, making possible the characterization of their temporal regulation and function in the B cell response and/or in B cell mediated disorders. Expression profiles, nucleic acids and proteins are provided for differing states of B cells, including resting, naive, activated, tolerant and immunosuppressed B cells. The present invention makes possible the identification and characterization of targets useful in prognosis, diagnosis, monitoring, rational drug design, and/or therapeutic intervention of immune system disorders.

Abstract: The present invention relates to the discovery, identification, and characterization of novel genes encoding proteins that share sequence similarity with animal zinc finger proteins. The invention encompasses the described polynucleotides, the encoded proteins, fusion proteins, polypeptides and peptides, genetically engineered animals that either under- or over-express the disclosed sequences, antibodies to the encoded proteins and peptides, host cell expression systems, antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed sequences that can be used for diagnosis, drug screening, clinical trial monitoring and the treatment of diseases and disorders.

Abstract: Described herein are methods that can be used for diagnosis of tissue remodeling, as well as tissue remodeling phenotypes. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate tissue remodeling. Additionally, molecular targets (genes and their products) for therapeutic intervention in disorders associated with tissue remodeling are described. Moreover, methods for using such molecular targets are described.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of angiogenic phenotypes and angiogenesis-associated diseases. Also described herein are methods that can be used to identify modulators of angiogenesis.

Abstract: Described herein are methods that can be used for diagnosis of angiogenesis and angiogenic phenotypes. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate angiogenesis. Additionally, molecular targets (genes and their products) for therapeutic intervention in disorders associated with angiogenesis are described. Moreover, methods for using such molecular targets are described.

Abstract: Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of angiogenic phenotypes and angiogenesis-associated diseases. Also described herein are methods that can be used to identify modulators of angiogenesis.

Abstract: Computer programs and computer-implemented methods are disclosed for extracting, analyzing and comparing data from biomolecular binding experiments. The invention receives a set of values corresponding to the interaction of one or more target samples with probes on one or more arrays of biomolecular probes, and uses the values to generate one or more probability values indicating the probability that a molecular species complementary to the probe set is not present in the target samples, or is present at levels greater than or less than one or more reference levels. The probability values are generated by comparing the values for individual probes in a probe set with values for a calibration set, which may include a null set, spiked probe sets, or housekeeping probe sets. Normalized experimental values are generated for sets of probes on the arrays using statistical methods. Data is output in the form of data files including normalized experimental values and probability values for probe sets in the arrays.

Abstract: Described herein are methods that can be used for diagnosis of angiogenesis and angiogenic phenotypes. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate angiogenesis. Additionally, molecular targets (genes and their products) for therapeutic intervention in disorders associated with angiogenesis are described. Moreover, methods for using such molecular targets are described.

Abstract: Described herein are methods that can be used for diagnosis of angiogenesis and angiogenic phenotypes. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate angiogenesis. Additionally, molecular targets (genes and their products) for therapeutic intervention in disorders associated with angiogenesis are described. Moreover, methods for using such molecular targets are described.

Abstract: The invention provides for the identification of all genes, whether known or novel, which are differentially expressed within and among B cells, making possible the characterization of their temporal regulation and function in the B cell response and/or in B cell mediated disorders. Expression profiles, nucleic acids and proteins are provided for differing states of B cells, including resting, naive, activated, tolerant and immunosuppressed B cells. The present invention makes possible the identification and characterization of targets useful in prognosis, diagnosis, monitoring, rational drug design, and/or therapeutic intervention of immune system disorders.